Navidea Biopharmaceuticals Inc (NAVB)

0.47
0.00 (0.00)
OTC : Health Care
Prev Close 0.47
Open 0.47
Day Low/High 0.46 / 0.48
52 Wk Low/High 0.47 / 2.50
Volume 188.46K
Avg Volume 380.90K
Exchange OTC
Shares Outstanding 161.90M
Market Cap 77.71M
EPS -0.10
P/E Ratio 1.06
Div & Yield N.A. (N.A)

Latest News

Navidea Biopharmaceuticals To Present At The 7th Annual LD Micro Invitational Investor Conference

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced it will...

Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) ("Navidea" or "the Company"), a company focused on the development and commercialization of precision immunodiagnostic agents, today announced its financial results for the...

Navidea Biopharmaceuticals Invited To Present Data At Two Major Upcoming Conferences

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) ("Navidea") ("the Company"), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced that it...

Navidea Provides Corporate Update And Reports Full Year 2016 Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today reported business and financial highlights for the fourth quarter and year ended December 31, 2016.

Navidea Completes Sale Of North American Rights Of Lymphoseek® To Cardinal Health

Navidea Biopharmaceuticals (NYSE MKT: NAVB) announced today the completion of the sale to Cardinal Health (NYSE: CAH) of its Lymphoseek® product for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic...

Navidea To Hold Conference Call To Provide Investor Update On Status Of Ongoing Corporate Events

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will hold an audio webcast conference call on Tuesday, January 31, 2017 at 4:30 p.

Navidea To Present At Upcoming Investor Conference

Navidea To Present At Upcoming Investor Conference

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will present at an upcoming investor conference.

Navidea Signs Asset Purchase Agreement With Cardinal Health

Navidea Signs Asset Purchase Agreement With Cardinal Health

Navidea Biopharmaceuticals (NYSE MKT: NAVB) today announced that it has entered into a definitive asset purchase agreement with Cardinal Health (NYSE: CAH).

Navidea Reports 2016 Third Quarter Financial Results

Navidea Reports 2016 Third Quarter Financial Results

Navidea Biopharmaceuticals (NYSE MKT:NAVB) reports financial results for the quarter ending September 30, 2016.

Navidea Biopharmaceuticals To Announce Third Quarter 2016 Financial Results On November 3, 2016

Navidea Biopharmaceuticals To Announce Third Quarter 2016 Financial Results On November 3, 2016

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the third quarter of 2016, on Thursday, November 3, 2016 prior to a conference call with the...

Navidea Appoints Michael M. Goldberg, M.D. President And Chief Executive Officer

Navidea Appoints Michael M. Goldberg, M.D. President And Chief Executive Officer

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that its Board of Directors has appointed Michael M.

Navidea Achieves $1 Million In Lymphoseek® Commercial Milestones

Navidea Achieves $1 Million In Lymphoseek® Commercial Milestones

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) has announced it will receive payments totaling $1 million from two recently achieved Lymphoseek ® commercial milestones under its distribution agreements with U.

Navidea's Lymphoseek® Receives Positive Opinion In Europe For A New Reduced Mass Vial

Navidea's Lymphoseek® Receives Positive Opinion In Europe For A New Reduced Mass Vial

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for a new Lymphoseek ® 50...

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade five under-$10 stocks that are within range of triggering big breakouts.

Navidea To Present At Upcoming Investor Conferences

Navidea To Present At Upcoming Investor Conferences

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will present at two upcoming investor conferences.

Navidea Biopharmaceuticals To Hold Investor Update Call

Navidea Biopharmaceuticals To Hold Investor Update Call

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced that the Company will hold an audio webcast conference call on Wednesday, September 7, 2016 at 8:30 a.

Navidea Biopharmaceuticals Enters Into Letter Of Intent With Cardinal Health For The Sale Of Lymphoseek® In North America

Navidea Biopharmaceuticals Enters Into Letter Of Intent With Cardinal Health For The Sale Of Lymphoseek® In North America

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has executed a Letter of Intent ("LOI") with Cardinal Health, Inc.

Navidea Biopharmaceuticals Announces 2016 Annual Meeting Results

Navidea Biopharmaceuticals Announces 2016 Annual Meeting Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced the results of voting at its 2016 Annual Meeting of Stockholders (the Annual Meeting) held August 11, 2016.

Navidea Executes A Term Sheet With Cerveau Technologies To Sublicense NAV4694

Navidea Executes A Term Sheet With Cerveau Technologies To Sublicense NAV4694

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announces the execution of a non-binding term sheet with Cerveau Technologies, Inc.

Navidea Reports Second Quarter 2016 Financial Results

Navidea Reports Second Quarter 2016 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced financial results for the second quarter of 2016.

Navidea Biopharmaceuticals To Announce Second Quarter 2016 Financial Results On August 4, 2016

Navidea Biopharmaceuticals To Announce Second Quarter 2016 Financial Results On August 4, 2016

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the second quarter of 2016, on Thursday, August 4, 2016 prior to a conference call with the investment...

Navidea Receives IRB Approval For Its Lymphoseek® Rheumatoid Arthritis Clinical Trial Protocol

Navidea Receives IRB Approval For Its Lymphoseek® Rheumatoid Arthritis Clinical Trial Protocol

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) announced that it has received Institutional Review Board (IRB) approval from the University of California, San Francisco School of Medicine for a clinical study examining...

Navidea Announces Presentation Of Results Demonstrating Performance Of Lymphoseek® In Breast Cancer At SNMMI

Navidea Announces Presentation Of Results Demonstrating Performance Of Lymphoseek® In Breast Cancer At SNMMI

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced results from three investigator-initiated studies that demonstrate beneficial performance characteristics of Lymphoseek® (technetium Tc 99m...

Navidea To Provide Shareholder Update

Navidea To Provide Shareholder Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announces a conference call on Wednesday, June 15, 2016 at 5:00 p.

Navidea Announces Data Presentations At 2016 Annual Meeting Of The Society Of Nuclear Medicine And Molecular Imaging (SNMMI)

Navidea Announces Data Presentations At 2016 Annual Meeting Of The Society Of Nuclear Medicine And Molecular Imaging (SNMMI)

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that results from investigator studies using Lymphoseek ® (technetium Tc 99m tilmanocept) injection are being presented at the 2016 Annual Meeting of...

$1.8 Million Fast-Track NIH SBIR Grant For Manocept™ Immunotherapeutics Evaluation In Kaposi's Sarcoma Awarded To Navidea

$1.8 Million Fast-Track NIH SBIR Grant For Manocept™ Immunotherapeutics Evaluation In Kaposi's Sarcoma Awarded To Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announces the receipt of an initial notice of award for a Fast- track Small Business Innovation Research (SBIR) grant providing for up to $1.

Navidea Provides Financing Update

Navidea Provides Financing Update

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced that it has received an unsolicited offer to refinance the entire existing CRG loan facility.

Navidea Reports First Quarter 2016 Financial Results

Navidea Reports First Quarter 2016 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced financial results for the first quarter of 2016.